NFE2L2 and neoplasm: Nrf2 pathway activation was assessed in PBMCs by measuring NAD(P)H:quinone oxidoreductase 1 (NQO1) mRNA expression, while tumor biopsies were examined via immunohistochemistry for markers related to inflammation, cell cycle progression, and apoptosis.